Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance

• 期刊名称The Journal of Rheumatology Supplement
• 作者Cantini, F.; Niccoli, L.; Goletti, D.
• 卷第91卷
• 印刷ISSN0380-0903
• 文件大小147.73KB
• 发表时间2014-05-01
• DOI10.3899/jrheum.140102
• 页码47-55